NEW YORK (GenomeWeb) – Biocept's stock faces a potential delisting from the Nasdaq due to a failure to comply with the minimum bid price requirement, the company said in a filing made yesterday with the US Securities and Exchange Commission.

Biocept received a notice from Nasdaq stating that it had failed to maintain a required minimum closing bid price of at least $1 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.